Previous Article | Next Article 
Journal of Clinical Microbiology, November 1998, p. 3188-3192, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Inducible
-Lactam Resistance in Aeromonas
hydrophila: Therapeutic Challenge for Antimicrobial
Therapy
Wen-Chien
Ko,1,2
Hsiu-Mei
Wu,3
Tsung-Chain
Chang,3
Jing-Jou
Yan,4 and
Jiunn-Jong
Wu3,*
Departments of Internal
Medicine1 and
Pathology,4 National Cheng Kung
University Hospital, and
Departments of
Medicine2 and
Medical
Technology,3 National Cheng Kung University
Medical College, Tainan, Taiwan
Received 3 March 1998/Returned for modification 20 April
1998/Accepted 3 August 1998
 |
ABSTRACT |
Despite the abundant amount of knowledge about inducible
chromosomally mediated
-lactamases among Aeromonas
species, extended-spectrum
-lactam-resistant A. hydrophila strains selected in clinical practice were rarely
reported. In the present study, two strains of A. hydrophila, A136 and A139, with markedly different
susceptibilities to extended-spectrum cephalosporins were isolated from
blood and the tip segment of an arterial catheter of a burn patient.
Another strain (A136m) was selected in vitro by culturing A136 in a
subinhibitory concentration of cefotaxime, the
-lactam agent
administered for the treatment of Aeromonas bacteremia in
this patient. Typing studies by arbitrarily primed PCR and pulsed-field
gel electrophoresis indicated a clonal relationship among strains A136,
A136m, and A139. These strains were identified to be of DNA
hybridization group 1. Wild-type strain A136 was resistant only to
ampicillin and cephamycins, but A136m and A139 were highly resistant to
the expanded- and broad-spectrum cephalosporins. The presence of
increased
-lactamase activity in A139 suggests that A139 is a
derepressed mutant which overexpresses
-lactamases. These results
call attention to the use of
-lactam agents for the treatment of
invasive Aeromonas infections.
 |
INTRODUCTION |
Species of the motile mesophilic
genus Aeromonas have been known to be pathogenic in
immunocompetent and compromised persons (13). They were
usually isolated from such clinical specimens as feces, blood, ascitic
fluid, and wound discharge or pus (12, 17).
Aeromonas infections also occur in hospital settings
(24), where they are immersed in the incremental pressure of
antibiotic selection. Antibiotic resistance will potentially become a
problem among Aeromonas strains causing nosocomial
infections.
The plasmid-mediated
-lactamases in enteric bacteria have been
studied and characterized extensively. The mechanisms mediating antibiotic resistance in clinical Aeromonas species were
elucidated recently. Chromosomally mediated, inducible
-lactamases
were recognized as the major mechanism of antibiotic resistance
(15). Aeromonas species were found to possess at
least three inducible chromosomally mediated
-lactamases
(34). The expression of genes encoding these three different
-lactamases was coordinated by a common regulatory pathway
(2). Derepressed mutants that constitutively produce
-lactamases have been selected in vitro from A. hydrophila, A. veronii, and A. caviae
(35). The evolution of
-lactam-sensitive
Aeromonas strains into
-lactam-resistant mutants during
-lactam therapy has been described only for A. caviae
(4). Here we report that the use of cefotaxime might promote
the development of
-lactam resistance in clinical A. hydrophila strains from a burn patient.
Brief clinical history.
A 62-year-old female was initially
healthy and suffered from a flame burn on 25 April 1995. The burn
covered about 61% of her total body surface area. On the next day she
was transferred to the burn center, which was a six-bed intensive care
unit of the National Cheng Kung University Hospital, Tainan, Taiwan.
After the initial standard care and escharotomy for her burn wound, she
was intubated for pulmonary inhalation injury. Fever appeared on the
second day of hospitalization, and gentamicin plus cephradine and then
gentamicin plus ampicillin-sulbactam were administered intravenously.
The fever persisted, and on the sixth day, the burn wounds deteriorated
and A. hydrophila was isolated from the wound and the blood.
On the seventh day, surgical debridement was performed. Intravenous
cefotaxime was given according to the in vitro susceptibility report
for the isolates described above. However, 3 days later A. hydrophila with the same antibiogram as the previous bacteremic
strain was cultured from the blood. On the 15th day, nosocomial
Candida albicans fungemia was detected. On the next day, a
strain of A. hydrophila resistant to cefotaxime was isolated
from the distal portion of the arterial indwelling catheter. The
antimicrobial therapy was adjusted and ciprofloxacin plus fluconazole
were given intravenously. The septic process was not halted, and acute
renal failure and pulmonary edema occurred. On the 38th day,
hypothermia, severe metabolic acidosis, and septic shock developed and
she died on the following day.
Nosocomial bacteremia and wound infections caused by
Aeromonas species were rarely encountered in our burn
center. Since there was no clustering of other patients with nosocomial
Aeromonas infection in the ward, no epidemiological survey
was carried out.
 |
MATERIALS AND METHODS |
Bacterial strains and identification.
Although four strains
of A. hydrophila were isolated from the patient during the
hospitalization, only the first bacteremic strain (A136) and the strain
from the arterial catheter (A139) were available. They were stored at
70°C for studies. Two reference strains of A. hydrophila
were purchased from the Culture Collection and Research Center (CCRC),
Hsinchu, Taiwan. CCRC 13018 is the same strain as ATCC 7966; CCRC 13881 is the same strain as ATCC 43414. Two randomly selected clinical
isolates of A. hydrophila, A2866 and A4252, from different
patients were used as the control group. The organisms were identified
to the genus and species levels by conventional methods
(14), and the identification was supplemented by the API-20E
system (bioMérieux Vitek, Hazelwood, Mo.).
Genomic species identification.
In phenotypic strains of
A. hydrophila, there are three DNA hybridization groups
(HGs). The identification of HG1 is presumptively based on growth on
DL-lactate (3). Identification of genomic species was further confirmed by rRNA gene restriction patterns and PCR
sequencing of 16S rRNA.
(i) rRNA gene restriction patterns.
Aeromonas sp.
strains A306 (HG1), A307 (HG2), and A308 (HG3) and plasmids pKK3535 and
pGML were kindly provided by M. Altwegg (University of Zurich, Zurich,
Switzerland). rRNA gene restriction patterns were used for
characterization of genomic species identification. The method was
based on one previously described by Lucchini and Altwegg
(23). In brief, the genomic DNA was extracted, and aliquots were digested with SmaI (New England Biolabs, Beverly,
Mass.). Fragments were separated in a 1.2% agarose gel in TBE
(Tris-borate-EDTA) buffer, stained with ethidium bromide, and
transferred to a nylon membrane, and the 567-bp HindIII
fragment of pGML1 containing the rrnB operon of
Escherichia coli was used as a probe. Methods of DNA
hybridization have been described previously (33).
(ii) PCR sequencing.
Nucleic acids were extracted by simple
mechanical lysis of bacterial cells as described by Kirschner et al.
(16). Finally, a 5-µl aliquot was used in a PCR. Primers
5'-AGAGTTTGATCATGGCTCAG-3' (forward) and
5'-GGTTACCTTGTTACGACTT-3' (reverse) (6), at
positions 8 to 27 and 1509 to 1491, respectively, of the E. coli numbering system, were used to generate a 1.4-kb fragment in
the 16S rRNA gene. A 50-µl PCR mixture contained each deoxynucleoside
triphosphate at a concentration of 200 µM, 1.25 U of Taq
polymerase (Applied Biosystems Division, Perkin-Elmer Corp., Norwalk,
Conn.), 1× PCR buffer and 0.5 µM (each) primer. The PCR protocol was
performed by the protocol of Borrell et al. (6). Sequencing
reactions were performed with the Taq DyeDeoxy terminator
cycle sequencing kit (Applied Biosystems Division, Perkin-Elmer Corp.)
with a GeneAmp PCR System 9600 (Perkin-Elmer Corp.) and a DNA Analysis
System 373 Stretch (Applied Biosystems Division, Perkin-Elmer Corp.). Both strands of the gene were sequenced with primers
5'-TGGAGGAATACCGGTGGCGA-3', at positions 704 to 723, and
5'-ATCTCTACGCATTTCACCGC-3', at positions 702 to 683, as well
as the primer pair used for PCR. The sequences obtained were compared
to known sequences in the GenBank database and were interpreted by
using the BlastN algorithm.
In vitro selection of mutants by a subinhibitory concentration of
cefotaxime.
According to the medical record, cefotaxime was the
-lactam agent used prior to isolation of the resistant strain. It
was likely that the use of cefotaxime offered the appropriate selective pressure for the emergence of a derepressed mutant. Thus, a
subinhibitory concentration of cefotaxime was used in vitro to select
resistant mutants. Wild-type strain A136 was grown overnight at 37°C
with 0.2 µg of cefotaxime per ml (one-fourth the MIC) in
Luria-Bertani (LB) broth. Cells that grew in the broth (strain A136m)
were subcultured and then saved for further MIC determinations.
In vitro susceptibility test.
Initially, the in vitro tests
for susceptibility to commonly used antibiotics were performed by the
disk diffusion method. The diameters of the inhibition zones were
measured and used for categorization of the strain as susceptible,
intermediate, or resistant as described by the National Committee for
Clinical Laboratory Standards (NCCLS) (26). The MICs for the
Aeromonas strains were determined with the E-test strip (AB
Biodisk, Solna, Sweden). Bacterial suspensions adjusted to a density
equivalent to that of a 0.5 McFarland standard were used as inocula for
determination of MICs with E-test strips. The interpretive breakpoint
concentrations were in accordance with those of NCCLS (27).
Characterization of genotype.
Two clinical isolates (A136
and A139) from the same patient, A136m, A. hydrophila CRCC
13018 and CRCC 13881, and two randomly selected clinical isolates of
the same species were investigated for genetic polymorphism. The
techniques of arbitrarily primed PCR (AP-PCR) and pulsed-field gel
electrophoresis (PFGE) were used to demonstrate the molecular
similarity.
(i) AP-PCR.
Two primers, ERIC-1R
(5'-ATGTAAGCTCCTGGGGATTCAC-3') and ERIC-2R
(5'-AAGTAAGTGACTGGGGTGAGCG-3'), were used for AP-PCR. The process of amplification was carried out in a GeneAmp PCR System 9600 (Perkin-Elmer Corp.). It was programmed for 4 cycles of 1 min at
94°C, 1 min at 37°C, and 2 min at 72°C, followed by 35 cycles of
1 min at 94°C, 1 min at 60°C, and 2 min at 72°C. The amplification products were separated by 1.2% agarose gel
electrophoresis, stained with ethidium bromide, and visualized with a
UV transilluminator.
(ii) Chromosomal DNA analysis by PFGE.
DNA embedded in
agarose beads was prepared as described by Piggot et al.
(29), with modifications. In brief, 30 ml of an overnight
culture in LB broth was harvested and washed with 1× TE (10 mM Tris
HCl [pH 7.5], 1 mM EDTA [pH 8.0]). The suspension was mixed with an
equal volume of 1% low-melting-temperature agarose and 2 volumes of
warm (42°C) paraffin oil. The mixtures were shaken vigorously for 2 min to form an emulsion. The emulsion was poured onto 10 ml of ice-cold
1× TE in a flask, and the contents of the flask were mixed by vigorous
shaking for 5 min. The agarose beads were harvested and suspended in 15 ml of T10E (10 mM Tris HCl [pH 7.5], 10 mM EDTA [pH 8.0]), and the
suspension was incubated at 37°C for 1 to 2 h with gentle
shaking. The beads were incubated overnight at 40 to 45°C in solution
C (1% sarcosyl, 0.4 M EDTA, 0.1 mg of protease K per ml), harvested by
centrifugation, and resuspended in 15 ml of TE buffer (pH 8.0)
containing 1 mM phenylmethylsulfonly fluoride and incubated for 2 h at room temperature with gentle shaking. The agarose beads were
digested with 10 U of SpeI (New Englands Biolabs) for
18 h and were electrophoresed through a 1% agarose gel in TBE
buffer at 8°C by using the contour-clamped homogeneous electric field
system (Pulsaphor plus; Pharmacia LKB Biotechnology, Uppsala, Sweden).
The conditions for electrophoresis were 150 V for 30 h, with pulse
times ranging from 5 to 35 s. The DNA bands were visualized by
staining the gel with ethidium bromide and were photographed.
Bacteriophage lambda DNA concatemers (Gibco BRL, Gaithersburg, Md.)
were used as size standards.
-Lactamase preparation.
The bacteria were grown overnight
with shaking in LB broth. The culture broth was diluted 20-fold in new
flasks containing 100 ml of LB broth. Following 2 h of incubation
at 37°C on an orbital shaker, cefotaxime was added as an inducer to
one flask to a final concentration of 0.2 µg per ml (one-fourth the
MIC), and incubation was continued for a further 4 h (or longer
for the derepressed mutant) until the optical density was 0.7. The cells were harvested, washed with phosphate buffer (pH 7.0) once, and
resuspended in the same phosphate buffer. The cells were then sonicated
two to four times in 30-s bursts at an amplitude of 12 to 24 µm with
intermediate cooling on ice. Major cell debris was removed by
ultracentrifugation. The supernatant was used for the
-lactamase
assays.
-Lactamase activity.
The qualitative detection of
-lactamase was performed with the Cefinase disk (BBL, Becton
Dickinson Microbiology Systems, Cockeyeville, Md.) according to the
manufacturer's instructions. The quantitative detection of
-lactamase was determined by a direct spectrophotometric assay in
1-cm-light-path cuvettes, with readings recorded at 30-s intervals for
5 min at a wavelength of 262 nm of optimal absorbance (28).
Cephalothin at a concentration of 0.1 mM was used as a substrate. The
protein concentration was determined by the method of Lowry et al.
(22) with the use of bovine serum albumin as the standard.
One enzyme unit is defined as the amount of enzyme that hydrolyzes 1 µmol of substrate/min/mg of protein.
 |
RESULTS |
In vitro susceptibility.
The results of in vitro
susceptibility testing by the disk diffusion method were as follows:
The initial isolate from blood (A136) and pus and the second isolate
from blood were sensitive to gentamicin, netilmicin, amikacin,
cefuroxime, cefotaxime and norfloxacin and resistant to ampicillin,
ampicillin-sulbactam, cephalothin, cefoxitin, and cefmetazole. Another
A. hydrophila isolate from the tip segment of an arterial
catheter (A139), however, was resistant to cefuroxime and cefotaxime.
The MICs for A136, A136m, A139 and two standard strains determined with
E-test strips are presented in Table 1.
The wild-type strain A136 had increased levels of resistance to most
cephalosporins and carbapenem compared to those for the two strains
from CCRC, although the MICs for A136 were still within the susceptible
range. Among three
-lactam-
-lactamase inhibitor combinations,
only piperacillin-tazobactam was active against the wild-type strain
but inactive against A139. All Aeromonas strains tested were
resistant to ticarcillin-clavulanic acid and amoxicillin-clavulanic
acid. Tremendous increases in the MICs for A139 were found, ranging
from 32- to several hundred-fold for several extended-spectrum
-lactam agents, including piperacillin, cefuroxime, cefotaxime,
ceftriaxone, and ceftazidime. However, the MICs of amikacin and
ciprofloxacin remained similar.
Selection of extended-spectrum
-lactam-resistant mutants in
vitro.
The antimicrobial susceptibility of A136m, an in
vitro-selected mutant, had patterns similar to those for A139 with two
exceptions, aztreonam and imipenem. The MICs of these two antibiotics
for A136m were eightfold less than those for A139 but were similar to
those for the wild-type strain.
Genomic species identification.
All three phenotypic A. hydrophila strains were able to grow on the DL-lactate
medium, which was characteristic for HG1. According to the rRNA gene
restriction patterns, all three strains were identical, and major bands
of HG1 were also found in these strains, as found in the reference
strain of HG1 (data not shown). In addition, 16S rRNA analysis showed
that all three strains were most closely related to A. hydrophila, with only one nucleotide difference (G to A) at
nucleotide position 471 compared to the sequence of A. hydrophila (GenBank accession no. X87271).
Characterization of genotype.
The results of AP-PCR and PFGE
are shown in Fig. 1 and 2, respectively. With primer ERIC-1R, the
amplification products of A136, A136m, and A139 were identical and
distinctly different from those of the other two clinical isolates and
the two strains from the American Type Culture Collection (Fig.
1). Similar results were obtained by
using primer ERIC-2R (data not shown). This was further confirmed by
PFGE. Chromosomal DNAs were digested with SpeI, and the
patterns for three strains (A136, A136m, and A139) were identical,
whereas the patterns for reference strains and unrelated clinical
strains were different (Fig. 2).

View larger version (114K):
[in this window]
[in a new window]
|
FIG. 1.
AP-PCR profiles for six strains of A. hydrophila obtained with primer ERIC-1R. Lane 1, A136; lane 2, A136m; lane 3, A139; lanes 4 and 5, two clinical strains of A. hydrophila, A2866 and A4252, respectively; lane 6, CCRC 13018;
lane 7, CCRC 13881; lane M, 100-bp DNA ladder used as a molecular size
standard.
|
|

View larger version (114K):
[in this window]
[in a new window]
|
FIG. 2.
PFGE separation of SpeI-digested chromosomal
DNA from A. hydrophila. Lane 1, A136; lane 2, A136m; lane 3, A139; lanes 4 and 5, two clinical strains of A. hydrophila,
A2866 and A4252, respectively; lane 6, CCRC 13018; lane 7, CCRC 13881;
lane M, bacteriophage lambda DNA concatemers.
|
|
-Lactamase activity.
With the Cefinase disk,
-lactamase
activity can be detected in the overnight colonies and cell extracts of
A139 and A136m but not in those of A136. Three strains (A136, A136m,
and A139) were further examined for their
-lactamase activities
against cephalothin. Cells extracted from A136, A136m, and A139 showed 0.04, 1.6, and 5.2 U of
-lactamase activity, respectively.
 |
DISCUSSION |
Aeromonas species are recognized as important infecting
microorganisms for patients with liver cirrhosis and malignancy
(13, 15, 17). Although the microorganisms are able to cause
nosocomial infections, aeromonads rarely cause infections in burn
patients. The colonization of burn wounds often preceded the occurrence of Aeromonas infections. Aquatic exposure is not essential
for A. hydrophila infections in burn wounds (5),
and suggestive clinical clues include a history of extinguishing the
fire with dirty water or rolling in dirt (30).
Aeromonas spp. had been shown to be susceptible to
tetracycline, chloramphenicol, cephalosporins, aminoglycosides, and
fluoroquinolones (19, 25). In the antibiotic era,
incremental increases in the levels of resistance of clinical strains
of Aeromonas to commonly used antibacterial agents have been
observed (18). In the study described in this report, it was
verified for the first time that a strain of A. hydrophila, the most common Aeromonas species causing human infections,
isolated from a burn patient acquired resistance to extended-spectrum
-lactam agents during antibiotic therapy with cefotaxime but
remained susceptible to aminoglycosides and fluoroquinolones.
Like enteric gram-negative bacilli, the emergence of resistance among
aeromonads will be accelerated by the clinical use of antibiotics.
Although plasmids encoding resistance to older cephalosporins were
reported in environmental and clinical Aeromonas isolates (7), the present knowledge of the
-lactam resistance in
Aeromonas species focused upon the chromosome-mediated
enzymes. In these species, an uncommon character has been discovered:
three chromosomally encoded, inducible
-lactamases are concurrently
found in A. janaeii and A. salmonicida (10,
35). These enzymes processed hydrolyzing activities for
cephalosporin, cloxacillin, and carbapenem, respectively. A recent
report further demonstrated that three
-lactamases were simultaneously overexpressed in mutants and that their expression might
be coordinated by a common regulatory system (2).
Initially, strain A136, isolated from blood, was susceptible in vitro
to cefotaxime; however, under the selective pressure of the
antibiotics, most likely cefotaxime, mutant A139 survived and became
resistant to cefotaxime. Because of the temporal relationship, the
increasing levels of resistance to broad-spectrum antibiotics, and the
identical genetic clonality demonstrated by AP-PCR and PFGE, A139 was
an in vivo resistant mutant of the wild-type strain. In addition, A139
had 130-fold more cephalothin-hydrolyzing activity than did A136.
Therefore, the former was regarded as a derepressed mutant from A136,
which overexpressed
-lactamase. A136m was an in vitro mutant
selected under the pressure of cefotaxime. In spite of their resistance
to cefotaxime, A136m and A139 possessed different susceptibilities to
imipenem and aztreonam. In addition, A139 had threefold more
cephalothin-hydrolyzing activity than A136m did. The mechanisms for
phenotypic variability between those genetically identical strains were
unclear. In a recent report, the frequency of in vitro production of
resistant mutants in Aeromonas was about 10
7
to 10
9, suggesting that a point mutation was responsible
for the generation of mutants (35). This appears to be
compatible with the theory of coordinating regulation of three
chromosomally mediated
-lactamases. The in vitro emergence of
derepressed mutants is noted to be universal in A. hydrophila and A. caviae but to be temperature
dependent in A. vernoii (35), and this suggests
that inducible
-lactam resistance will be a common threat in
treating Aeromonas species infections.
Inducible chromosomally encoded
-lactamases mediating resistance to
extended-spectrum
-lactam agents have been well characterized in
Enterobacter cloacae, Citrobacter freundii, and
Pseudomonas aeruginosa (21). Clinically, the
frequency of the development of inducible resistance during
-lactam
treatment of Enterobacter infections varies from less than
20% to more than 70% (32), and the coadministration of an
aminoglycoside with a
-lactam did not prevent the emergence of
resistance to
-lactam agents (8). As for the genus
Aeromonas, our clinical experience in treating
Aeromonas bacteremia indicates that the emergence of resistance resulting from the selective pressure exerted by a
-lactam was a rare event. It is likely that the heavy colonization of Aeromonas species on the ischemic and damaged integument
of the burn patient resulted in a high inoculum of bacteria immersed in
a subinhibitory concentration of antibiotic, which favors the emergence
of resistant mutants. The impact of simultaneous administration of
aminoglycosides for the prevention of cephalosporin resistance during
therapy with a cephalosporin for Aeromonas infections
remains unknown.
AP-PCR has been widely used in the epidemiological typing of many
pathogens, including Clostridium difficile (20),
Legionella pneumophila (1), Streptococcus
mutans (31), P. aeruginosa (11),
and Vibrio cholerae (9). However, the application
of AP-PCR for A. hydrophila typing has not been reported. In
this study, we showed that, despite a small number of isolates, AP-PCR could easily demonstrate the same genetic fingerprints for A136 and
A139 and could distinguish the former isolates from four genetically unrelated strains; this result was further confirmed by PFGE. Therefore, it is suggested that AP-PCR is a rapid and simple typing method for genotypic investigations of clinical isolates of A. hydrophila.
In conclusion, the present report demonstrated that the emergence of
cephalosporin-resistant mutants from a wild-type strain might cause
therapeutic failure in the treatment of invasive Aeromonas infections. Therefore, clinicians should closely observe clinical and
microbiological responses to cephalosporins when patients with such
infections are treated with these drugs.
 |
ACKNOWLEDGMENTS |
We thank the Division of Clinical Microbiology, Department of
Pathology National Cheng Kung University Hospital, for kindly supplying
the bacterial strains used in this study.
This project was partly supported by a grant (NSC 87-2314-B-006-017)
from the National Science Council, Taiwan, Republic of China.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Technology, National Cheng Kung University Medical College, No. 1 University Rd., Tainan, Taiwan. Phone: 886-6-2353535, ext. 5775. Fax:
886-6-2363956. E-mail: jjWu{at}mail.ncku.edu.tw.
 |
REFERENCES |
| 1.
|
Alexiou-Daniel, S.,
A. Papoutsi,
A. Papa,
A. Lambropoulos, and A. Antoniadis.
1996.
Typing of Legionella pneumophila strains isolated in Greece by arbitrarily-primed PCR.
Cell. Mol. Biol.
42:833-838.
|
| 2.
|
Alksne, L. A., and B. A. Rasmussen.
1997.
Expression of the AsbA1, OXA-12, and AsbM1 -lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon.
J. Bacteriol.
179:2006-2013[Abstract/Free Full Text].
|
| 3.
|
Altwegg, M.,
A. G. Steigerwalt,
R. Altwegg-Bissig,
J. Luthy-Hottenstein, and D. J. Brenner.
1990.
Biochemical identification of Aeromonas genospecies isolated from humans.
J. Clin. Microbiol.
28:258-264[Abstract/Free Full Text].
|
| 4.
|
Bakken, J. S.,
C. C. Sanders,
R. B. Clark, and M. Hori.
1988.
-Lactam resistance in Aeromonas spp. caused by inducible -lactamase active against penicillins, cephalosporins, and carbapenems.
Antimicrob. Agents Chemother.
32:1314-1319[Abstract/Free Full Text].
|
| 5.
|
Barillo, D. J.,
A. T. McManus,
W. G. Cioffi,
W. F. McManus,
S. H. Kim, and B. A. Pruitt, Jr.
1996.
Aeromonas bacteremia in burn patients.
Burns
22:48-52[Medline].
|
| 6.
|
Borrell, N.,
S. G. Acinas,
M. J. Figueras, and A. J. Martinez-Murcia.
1997.
Identification of Aeromonas clinical isolates by restriction fragment length polymorphism of PCR-amplified 16S rRNA genes.
J. Clin. Microbiol.
35:1671-1674[Abstract].
|
| 7.
|
Chaudhury, A.,
G. Nath,
B. N. Shukla, and S. C. Sanyal.
1996.
Biochemical characterization, enteropathogenicity and antimicrobial resistance plasmids of clinical and environmental Aeromonas isolates.
J. Med. Microbiol.
44:434-437[Abstract].
|
| 8.
|
Chow, J. W.,
M. J. Fine,
D. M. Shales,
J. P. Quinn,
D. C. Hooper,
M. P. Johnson,
R. Ramphal,
M. M. Wagener,
D. K. Miyashiro, and V. L. Yu.
1991.
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.
Ann. Intern. Med.
115:585-590.
|
| 9.
|
Coelho, A.,
A. C. Vicente,
M. A. Baptista,
H. Momen,
F. A. Santos, and C. A. Salles.
1995.
The distinction of pathogenic Vibrio cholerae groups using arbitrarily primed PCR fingerprints.
Res. Microbiol.
146:671-683[Medline].
|
| 10.
|
Hayes, M. V.,
C. J. Thomson, and S. G. B. Amyes.
1994.
Three -lactamases isolated from Aeromonas salmonicida, including a carbapenemase not detectable by conventional methods.
Eur. J. Clin. Microbiol. Infect. Dis.
13:805-811[Medline].
|
| 11.
|
Hernandez, J.,
M. A. Ferrus,
M. Hernandez, and R. J. Owen.
1997.
Arbitrary primed PCR fingerprinting and serotyping of clinical Pseudomonas aeruginosa strains.
FEMS Immunol. Med. Microbiol.
17:37-47[Medline].
|
| 12.
|
Holmberg, S. D.,
W. L. Schell,
G. R. Fanning,
I. K. Wachsmuth,
F. W. Hickman-Brenner,
P. A. Blake,
D. J. Brenner, and J. J. Farmer, III.
1986.
Aeromonas intestinal infections in the United States.
Ann. Intern. Med.
105:683-689.
|
| 13.
|
Janda, J. M., and P. S. Duffey.
1988.
Mesophilic aeromonads in human disease: current taxonomy, laboratory identification, and infectious disease spectrum.
Rev. Infect. Dis.
10:980-997[Medline].
|
| 14.
|
Janda, J. M.,
S. L. Abbott, and A. M. Carnahan.
1995.
Aeromonas and Plesiomonas, p. 477-482.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
|
| 15.
|
Jones, B. L., and M. H. Wilcox.
1995.
Aeromonas infections and their treatment.
J. Antimicrob. Chemother.
35:453-461[Abstract/Free Full Text].
|
| 16.
|
Kirschner, P.,
B. Springer,
U. Vogel,
A. Meier,
A. Wrede,
M. Kiekerbeck,
F. C. Bange, and E. C. Böttger.
1993.
Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory.
J. Clin. Microbiol.
31:2882-2889[Abstract/Free Full Text].
|
| 17.
|
Ko, W. C., and Y. C. Chuang.
1995.
Aeromonas bacteremia: review of 59 episodes.
Clin. Infect. Dis.
20:1298-1304[Medline].
|
| 18.
|
Ko, W. C.,
K. K. Yu,
C. Y. Liu,
C. T. Huang,
H. H. Leu, and Y. C. Chuang.
1996.
Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan.
Antimicrob. Agent Chemother.
40:1260-1262[Abstract].
|
| 19.
|
Koehler, J. M., and L. R. Ashdown.
1993.
In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents.
Antimicrob. Agents Chemother.
37:905-907[Abstract/Free Full Text].
|
| 20.
|
Lemann, F.,
C. Chambon,
F. Barbut,
C. Gardin,
J. Briere,
N. Lambert-Zechovsky, and C. Branger.
1997.
Arbitrary primed PCR rules out Clostridium difficile cross-infection among patients in a haematology unit.
J. Hosp. Infect.
35:107-115[Medline].
|
| 21.
|
Lindberg, F.,
S. Lindquist, and S. Normark.
1988.
Genetic basis of induction and overproduction of chromosome class I -lactamase in nonfastidious gram-negative bacilli.
Rev. Infect. Dis.
10:782-785[Medline].
|
| 22.
|
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and R. J. Randall.
1951.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275[Free Full Text].
|
| 23.
|
Lucchini, G. M., and M. Altwegg.
1992.
rRNA gene restriction patterns as taxonomic tools for the genus Aeromonas.
Int. J. Syst. Bacteriol.
42:384-389[Abstract/Free Full Text].
|
| 24.
|
Mellersh, A. R.,
P. Norman, and G. H. Smith.
1984.
Aeromonas hydrophila: an outbreak of hospital infection.
J. Hosp. Infect.
5:425-430[Medline].
|
| 25.
|
Motyl, M. R.,
G. McKinley, and J. M. Janda.
1985.
In vitro susceptibilities of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimicrobial agents.
Antimicrob. Agents Chemother.
28:151-153[Abstract/Free Full Text].
|
| 26.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disks susceptibility tests, 6th ed. Approved standard M2-A6.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 27.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grew aerobically, 4th ed. Approved standard M7-A4.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 28.
|
O'Callaghan, C. H.,
P. M. Muggleton, and G. W. Ross.
1969.
Effects of -lactamase from gram-negative organisms on cephalosporins and penicillins.
Antimicrob. Agents Chemother.
13:57-63.
|
| 29.
|
Piggot, P. J.,
M. Amjad,
J. J. Wu,
H. Sandoval, and J. Castro.
1990.
Genetic and physical maps of Bacillus subtilis 168, p. 493-543.
In
C. R. Harwood, and S. M. Cutting (ed.), Molecular biology methods for bacillus. John Wiley & Sons Ltd., West Sussex, England.
|
| 30.
|
Purdue, G. F., and J. L. Hunt.
1988.
Aeromonas hydrophila infection in burn patients.
Burns
14:220-221.
|
| 31.
|
Saarela, M.,
J. Hannula,
J. Matto,
S. Asikainen, and S. Alaluusua.
1996.
Typing of mutans streptococci by arbitrarily primed polymerase chain.
Arch. Oral Biol.
41:821-826[Medline].
|
| 32.
|
Sanders, W. E., and C. C. Sanders.
1997.
Enterobacter spp.: pathogens poised to flourish at the turn of the century.
Clin. Microbiol. Rev.
10:220-241[Abstract].
|
| 33.
|
Tsai, P. J.,
C. F. Kuo,
K. Y. Lin,
Y. S. Lin,
H. Y. Lei,
F. F. Chen,
J. R. Wang, and J. J. Wu.
1998.
Effect of group A streptococcal cysteine protease on invasion of epithelial cells.
Infect. Immun.
66:1460-1466[Abstract/Free Full Text].
|
| 34.
|
Walsh, T. R.,
D. J. Payne,
A. P. MacGowan, and P. M. Bennett.
1995.
A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible -lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity.
J. Antimicrob. Chemother.
35:271-279[Abstract/Free Full Text].
|
| 35.
|
Walsh, T. R.,
R. A. Stunt,
J. A. Nabi,
A. P. MacGowan, and P. M. Bennett.
1997.
Distribution and expression of -lactamase genes among Aeromonas spp.
J. Antimicrob. Chemother.
40:171-178[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, November 1998, p. 3188-3192, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Libisch, B., Giske, C. G., Kovacs, B., Toth, T. G., Fuzi, M.
(2008). Identification of the First VIM Metallo-{beta}-Lactamase-Producing Multiresistant Aeromonas hydrophila Strain. J. Clin. Microbiol.
46: 1878-1880
[Abstract]
[Full Text]
-
Poole, T. L., Callaway, T. R., Bischoff, K. M., Warnes, C. E., Nisbet, D. J.
(2006). Macrolide inactivation gene cluster mphA-mrx-mphR adjacent to a class 1 integron in Aeromonas hydrophila isolated from a diarrhoeic pig in Oklahoma. J Antimicrob Chemother
57: 31-38
[Abstract]
[Full Text]
-
Ko, W.-C., Chiang, S.-R., Lee, H.-C., Tang, H.-J., Wang, Y.-Y., Chuang, Y.-C.
(2003). In Vitro and In Vivo Activities of Fluoroquinolones against Aeromonas hydrophila. Antimicrob. Agents Chemother.
47: 2217-2222
[Abstract]
[Full Text]
-
Ko, W.-C., Lee, H.-C., Chuang, Y.-C., Ten, S.-H., Su, C.-Y., Wu, J.-J.
(2001). In Vitro and in Vivo Combinations of Cefotaxime and Minocycline against Aeromonas hydrophila. Antimicrob. Agents Chemother.
45: 1281-1283
[Abstract]
[Full Text]